EUVIMEDEUVIMED entdecken
Crossref

Blood‐based biomarkers for Alzheimer's disease

Priyanka Chohan, Mark Dashwood, George Theodoulou, Hannah Reed, Tarun Kuruvilla

Progress in Neurology and Psychiatry · 2022-10 · 26 (4) · 10-14

DOI: 10.1002/pnp.764 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Progress in Neurology and Psychiatry, online erschienen am 08.11.2022. Verfasst von Priyanka Chohan und 4 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Blood‐based biomarkers for identifying Alzheimer's disease (AD) pathology have been of considerable interest over the past decade and can offer a significant advantage over the currently available and validated cerebrospinal fluid and positron emission tomography biomarkers in terms of cost, invasiveness and accessibility. This review explores the role of three blood‐based biomarkers; plasma amyloid β, tau and neurofilament light chain, and their combination, in the identification of AD pathology and how they may be utilised in clinical practice.

Zitieren

APA

Chohan, P., Dashwood, M., Theodoulou, G., Reed, H., & Kuruvilla, T. (2022). Blood‐based biomarkers for Alzheimer's disease. Progress in Neurology and Psychiatry, 26(4), 10-14. https://doi.org/10.1002/pnp.764

Vancouver

Chohan P, Dashwood M, Theodoulou G, Reed H, Kuruvilla T. Blood‐based biomarkers for Alzheimer's disease. Progress in Neurology and Psychiatry. 2022;26(4):10-14. doi:10.1002/pnp.764

BibTeX
@article{Chohan2022,
  author = {Chohan, Priyanka and Dashwood, Mark and Theodoulou, George and Reed, Hannah and Kuruvilla, Tarun},
  title = {Blood‐based biomarkers for Alzheimer's disease},
  journal = {Progress in Neurology and Psychiatry},
  year = {2022},
  volume = {26},
  number = {4},
  pages = {10--14},
  doi = {10.1002/pnp.764}
}
Kostenlos starten →